EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability

Alise K Carlson, Moein Amin, Jeffrey A Cohen

Drugs · 2024-03 · 84 (3) · 285-304

DOI: 10.1007/s40265-024-02011-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs, online erschienen am 14.03.2024. Verfasst von Alise K Carlson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Mellen Center, Neurologic Institute, Cleveland Clinic, 9500 Euclid Ave U10, Cleveland, OH, 44195, USA. Hauptthemen laut MEDLINE: Multiple Sclerosis. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently, there are four monoclonal antibodies (mAbs) that target the cluster of differentiation (CD) 20 receptor available to treat multiple sclerosis (MS): rituximab, ocrelizumab, ofatumumab, and ublituximab. B-cell depletion therapy has changed the therapeutic landscape of MS through robust efficacy on clinical manifestations and MRI lesion activity, and the currently available anti-CD20 mAb therapies for use in MS are a cornerstone of highly effective disease-modifying treatment. Ocrelizumab is currently the only therapy with regulatory approval for primary progressive MS. There are currently few data regarding the relative efficacy of these therapies, though several clinical trials are ongoing. Safety concerns applicable to this class of therapeutics relate primarily to immunogenicity and mechanism of action, and include infusion-related or injection-related reactions, development of hypogammaglobulinemia (leading to increased infection and malignancy risk), and decreased vaccine response. Exploration of alternative dose/dosing schedules might be an effective strategy for mitigating these risks. Future development of biosimilar medications might make these therapies more readily available. Although anti-CD20 mAb therapies have led to significant improvements in disease outcomes, CNS-penetrant therapies are still needed to more effectively address the compartmentalized inflammation thought to play an important role in disability progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisHumansRituximabAntigens, CD20

Substanzen

RituximabAntigens, CD20

Autor:innen und Institutionen

  • Mellen Center, Neurologic Institute, Cleveland Clinic, 9500 Euclid Ave U10, Cleveland, OH, 44195, USA.
  • Mellen Center, Neurologic Institute, Cleveland Clinic, 9500 Euclid Ave U10, Cleveland, OH, 44195, USA. cohenj@ccf.org.

Zitieren

APA

Carlson, A. K., Amin, M., & Cohen, J. A. (2024). Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability. Drugs, 84(3), 285-304. https://doi.org/10.1007/s40265-024-02011-w

Vancouver

Carlson AK, Amin M, Cohen JA. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability. Drugs. 2024;84(3):285-304. doi:10.1007/s40265-024-02011-w

BibTeX
@article{Carlson2024,
  author = {Carlson, Alise K and Amin, Moein and Cohen, Jeffrey A},
  title = {Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability},
  journal = {Drugs},
  year = {2024},
  volume = {84},
  number = {3},
  pages = {285--304},
  doi = {10.1007/s40265-024-02011-w}
}
Kostenlos starten →